Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Strategy analysis > KOL Insight

KOL Insight


  • Sort by Random
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 45 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page

  • Post-ADPD Alzheimer’s Disease KOL Interview

    $599.00

    Key Highlights BIIB-037 Amyloid beta PET data show positive Abeta reduction; cognitive results are not interpretable with such small numbers. (BIIB) BIIB-037 Phase Ib result interpretation may be effected by the ApoE4 dropouts in the treatment arm. (BIIB) MK-8931 and BIIB-037 show sufficient target engagement, but there is no evidence to date that amyloid clearance […]

    April 8, 2015
    Find out more
  • Abuse-Deterrent Opioids Survey

    Abuse-Deterrent Opioids Survey KOL Interview

    $599.00

    Biomedtracker performed a 5-question survey of 30 United States primary care physicians who currently treat patients with chronic pain and prescribe opioids to at least some of their patients with chronic pain to gauge current and future use of abuse-deterrent opioids to treat chronic pain.

    March 9, 2017
    Find out more

  • Ulcerative Colitis (UC) KOL Interview – UK

    $599.00

    A UK expert in the ulcerative colitis (UC) field dives into the treatment algorithm, critical unmet needs, and pipeline drugs, such as the Janus kinase inhibitors and sphingosine 1-phosphate (S1P) modulators.

    March 1, 2021
    Find out more

  • Post-EASL KOL Interview

    $599.00

    Highlights KOL believes elsbasvir and grazoprevir data will lead to approval and look similar to available drugs on the market (MRK). Post-liver transplant data for sofosbuvir and simpeprevir was positive (GLD, JNJ). Three DAA combination of -5816,-9857, and sofosbuvir looked good, but most physicians are erring on the side of conservative 12- week treatment regimens […]

    May 29, 2015
    Find out more

  • Asthma and COPD KOL Interview

    $599.00

    KOL thinks that the biggest challenge to treating COPD is cost, even with a very low population of uninsured people.

    February 29, 2016
    Find out more
  • Datamonitor-Acute-Myelogenous-Leukemia-KOL-Interview

    Acute Myelogenous Leukemia (AML) KOL Interview

    $599.00

    Datamonitor interviewed three oncology specialists to determine the physicians’ views on marketed and pipeline therapies for Acute Myelogenous Leukemia. Two physicians were based in the US (Greater Midwest and Greater Boston areas) and one in the UK. The three interviews were combined into a single report.

    August 19, 2016
    Find out more

  • Schizophrenia and Bipolar Disorder KOL Interview – Germany

    $599.00

    This interview with an EU-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

    April 28, 2021
    Find out more

  • Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – UK

    $599.00

    This interview covers hepatocellular carcinoma (HCC) treatment trends in the UK. We discuss current options for first- and second-line treatment, as well as therapies that are currently in Phase III clinical trials.

    February 6, 2019
    Find out more

  • Bladder Cancer KOL Interview – US

    $599.00

    A US KOL provides insight into the current treatment landscape for bladder cancer. Critical unmet needs in the bladder cancer market along with future trends are also discussed.

    May 31, 2019
    Find out more
  • Atopic Dermatitis and Psoriasis KOL Interview – US, Northeast

    Atopic Dermatitis and Psoriasis KOL Interview – US, Northeast

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

    November 18, 2021
    Find out more

  • Datamonitor Healthcare Non-Alcoholic Steatohepatitis (NASH) KOL Interview – France

    $599.00

    This interview with a French key opinion leader (KOL) provides insight into pipeline therapies for non-alcoholic steatohepatitis (NASH), as well as pricing strategies and future treatment rates for the different fibrosis stages of NASH.

    May 20, 2019
    Find out more

  • Datamonitor Healthcare Infectious Diseases Disease Analysis: Seasonal Influenza Vaccines

    $599.00

    The seasonal influenza vaccines market in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) is expected to continue to expand over the next 10 years, largely due to the continued uptake of premium-priced vaccines in the elderly subgroup, including quadrivalent forms of Fluzone High-Dose (HD) and Fluad, as well as the launch of the first-in-class adjuvanted nanoparticle vaccine, NanoFlu.

    October 30, 2020
    Find out more

  • Triple-Negative Breast Cancer KOL Interview – US

    $599.00

    A US-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.

    October 3, 2019
    Find out more
  • Acute Myeloid Leukemia (AML) KOL Interview – UK

    Acute Myeloid Leukemia (AML) KOL Interview – UK

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for acute myeloid leukemia (AML). Critical unmet needs are also discussed. Key pipeline assets highlighted include idasanutlin, oral azacitidine, and pevonedistat.

    March 14, 2022
    Find out more

  • Biomedtracker Q3 2017 Outlook Report

    $599.00

    In this report, we cover catalysts from 21 drugs expected to occur in Q3 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

    August 2, 2017
    Find out more

  • Datamonitor Healthcare Systemic Lupus Erythematosus KOL Interviews

    $599.00

    Datamonitor Healthcare interviewed two experts on systemic lupus erythematosus (SLE) based in the US to gauge their views on currently available treatment options, pipeline drugs and challenges with clinical trial design in SLE.

    August 18, 2017
    Find out more

  • Pediatric Acute Leukemias (AML/ALL) KOL Interview

    $599.00

    Highlights Current manufacturing turnaround times for CAR-T products (2-3 weeks) for ALL are not a major limitation for pediatric leukemia patients. CAR-T treatments may be more acutely toxic than transplant immediately after infusion, but patients may have fewer medium- and long-term complications. Agents that target the cell cycle (CDK inhibitors, Aurora kinase inhibitors) will likely […]

    April 1, 2015
    Find out more

  • Alzheimer’s Disease KOL Interview – US, South

    $599.00

    This interview with a US key opinion leader (KOL) provides insight into data from various late-phase Alzheimer’s disease pipeline therapies, as well as a discussion of the design of these trials. Also discussed are treatment trends and current unmet needs.

    January 28, 2019
    Find out more
  • Respiratory Syncytial Virus (RSV) Prevention KOL Interview – UK

    Respiratory Syncytial Virus (RSV) Prevention KOL Interview – UK

    $599.00

    This interview with a UK-based key opinion leader (KOL) provides insights into upcoming changes in treatment algorithms, trial data for late-phase pipeline prophylaxis therapies, competitive positioning, and vaccination coverage rates. Pricing and reimbursement, as well as unmet needs, are also discussed. Key pipeline assets highlighted include nirsevimab, RSVpreF, and GSK3844766A.

    December 22, 2021
    Find out more
  • Non-Small Cell Lung Cancer KOL Interview

    Non-Small Cell Lung Cancer KOL Interview

    $599.00

    Biomedtracker interviewed a lung cancer specialist based in the US to determine his views on the non-small cell lung cancer treatment landscape, with a focus on PD-1 immunotherapies.

    December 16, 2016
    Find out more

  • Datamonitor Healthcare Type 2 Diabetes KOL Interview – Italy

    $599.00

    In this interview with an Italian KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

    October 12, 2018
    Find out more

  • Rheumatoid Arthritis KOL Interview – New Jersey, US

    $599.00

    A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

    July 31, 2019
    Find out more

  • Rheumatoid Arthritis KOL Interview – California, US

    $599.00

    A US-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

    July 31, 2019
    Find out more
  • Chronic Lymphocytic Leukemia (CLL) KOL Interview – Italy

    Chronic Lymphocytic Leukemia (CLL) KOL Interview – Italy

    $599.00

    An Italy-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Key pipeline assets highlighted include non-covalent BTK inhibitors, Brukinsa, and CD19-directed CAR-T therapies.

    March 17, 2022
    Find out more

  • Datamonitor Healthcare Type 2 Diabetes KOL Interview – UK

    $599.00

    In this discussion with a UK KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

    October 12, 2018
    Find out more

  • Congestive Heart Failure Pulse Survey

    $599.00

    The study was just closed early, as LCZ696 increased time to first occurrence of either

    cardiovascular death or heart failure hospitalization, though details have not been released.

    We surveyed 10 US Cardiologists to get a preview of how they would use LCZ696 under different

    assumptions about what the study found.

    April 1, 2014
    Find out more

  • Multiple Myeloma KOL Interview – UK

    $599.00

    This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for multiple myeloma. Drug adverse events and UK market access issues are also discussed. Key therapies highlighted include Darzalex, Venclexta, Xpovio, Ygalo, Blenrep, and BCMA-targeted CAR-T therapies.

    May 15, 2020
    Find out more

  • Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – US

    $599.00

    An interview with a US key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, and addressing unmet needs.

    November 9, 2018
    Find out more

  • Datamonitor Healthcare Major Depressive Disorder KOL Interview – US #1

    $599.00

    A US key opinion leader (KOL) discusses key late-phase pipeline and marketed drugs for major depressive disorder and highlights the significance of unique mechanisms of action in the market.

    October 2, 2018
    Find out more

  • Datamonitor Meningococcal Vaccines KOL Interview

    $599.00

    Datamonitor interviewed an infectious diseases specialist based in the US Greater Washington DC area to determine this physician’s views on marketed and pipeline meningococcal vaccines.

    July 12, 2016
    Find out more
  • Acute Myeloid Leukemia (AML) KOL Interview – Italy

    Acute Myeloid Leukemia (AML) KOL Interview – Italy

    $599.00

    An interview with an Italian key opinion leader (KOL) in which they provide insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for AML. Key assets highlighted include Venclexta, Onureg, Idhifa, Tibsovo, magrolimab, crenolanib, gilteritinib, and Iomab-B.

    March 14, 2022
    Find out more

  • Anemia in Chronic Kidney Disease Pricing & Reimbursement KOL Interview – US, Southwest

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into pricing and reimbursement dynamics and issues concerning anemia in chronic kidney disease, with a focus on the anticipated reimbursement of HIF stabilizers in the US.

    June 30, 2020
    Find out more

  • Ovarian Cancer Pulse Survey

    $599.00

    Diagnostics/diagnostic techniques discussed:

    etarfolatide/folic acid, BRCA mutation testing

    May 7, 2014
    Find out more

  • Head and Neck Cancer KOL Interview – UK

    $599.00

    This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for head and neck cancer. Disease stratification by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key pipeline assets highlighted include Imfinzi, Bavencio, tremelimumab, and Tecentriq.

    April 14, 2020
    Find out more

  • Datamonitor Axial Spondyloarthritis KOL Interviews

    $599.00

    Datamonitor interviewed three arthritis specialists, one based each in France, Italy and the US, to gauge their views on currently available treatment options, pipeline drugs, biosimilars and treatment challenges in axial spondyloarthritis (axSpA). The three interviews were combined into a single report.

    March 9, 2017
    Find out more

  • Human Papillomavirus (HPV) KOL Interview – US, Midwest

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing trends, marketed vaccines, and vaccination coverage rates, as well as commentary on vaccination strategies in different markets. The marketed vaccines discussed include Cervarix, Gardasil, and Gardasil 9.

    January 3, 2020
    Find out more
  • Colorectal Cancer KOL Interview – US, Northeast

    Colorectal Cancer KOL Interview – US, Northeast

    $599.00

    This interview with a US-based key opinion leader (KOL) provides insights into current prescribing habits, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for colorectal cancer. Key assets highlighted include Avastin/bevacizumab, Erbitux, Vectibix, Mektovi, Braftovi, Cyramza, Lonsurf, Jemperli, Opdivo, Yervoy, Tecentriq, Cosela, Modufolin, fruquintinib, adagrasib, and sotorasib.

    May 23, 2022
    Find out more

  • Datamonitor Healthcare Seasonal Influenza Vaccines KOL Interview – UK

    $599.00

    An interview with a UK key opinion leader (KOL) on seasonal influenza vaccination coverage rates and trends in main risk groups, key marketed vaccines, pipeline approaches, and the potential for a universal influenza vaccine.

    November 19, 2018
    Find out more

  • 2016 Biomedtracker Post-EASL Hepatitis C Survey

    $599.00

    We performed a 9-question survey of 29 EU and 31 US hepatologists and gastroenterologists after the European Association of the Study of the Liver (EASL) International Liver Conference (ILC) from April, 2016 in Barcelona to gauge current and projected prescribing practices for hepatitis C virus (HCV) infection.

    May 16, 2016
    Find out more

  • Rheumatoid Arthritis KOL Interview – UK

    $599.00

    A UK-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis, including upadacitinib and filgotinib.

    July 31, 2019
    Find out more

  • Post-AAIC KOL Interview

    $599.00

    Crenezumab data was negative in a Phase II study in mild to moderate AD. The signal in not pre-specified isn’t convincing. These data likely will have ethical implications for the asymptomatic, genetic AD predisposition study in the Columbian trial.

    August 6, 2014
    Find out more
  • Chronic Lymphocytic Leukemia (CLL) KOL Interview – Germany

    Chronic Lymphocytic Leukemia (CLL) KOL Interview – Germany

    $599.00

    A Germany-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for CLL. Pipeline therapies discussed include Brukinsa, U2 regimen, non-covalent BTK inhibitors, and CD19-directed CAR-T therapy.

    March 17, 2022
    Find out more

  • 2015 Post-AAIC KOL Interview

    $599.00

    Following the 2015 Alzheimer’s Association International Conference (AAIC), we interviewed an Alzheimer’s Disease expert on his opinion of the data presentations and the future of Alzheimer’s Disease treatment.

    August 1, 2015
    Find out more

  • Post-EASL KOL Insight Interview

    $599.00

    The European Association for the Study of the Liver (EASL) held the 2014 International Liver Meeting in
    London from April 9-13. The main focus of this year’s meeting was the clinical use of currently approved and
    soon-to-be approved, direct-acting antivirals for Hepatitis C.

     

    May 6, 2014
    Find out more

  • Datamonitor Healthcare HIV KOL Interview – US #2

    $599.00

    A US key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

    January 25, 2019
    Find out more
Page 1 of 5
Page 1 of 512345
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top